全文获取类型
收费全文 | 121958篇 |
免费 | 13455篇 |
国内免费 | 4085篇 |
专业分类
耳鼻咽喉 | 827篇 |
儿科学 | 1859篇 |
妇产科学 | 1351篇 |
基础医学 | 22444篇 |
口腔科学 | 3153篇 |
临床医学 | 8317篇 |
内科学 | 18387篇 |
皮肤病学 | 2089篇 |
神经病学 | 12897篇 |
特种医学 | 3036篇 |
外国民族医学 | 32篇 |
外科学 | 9484篇 |
综合类 | 12920篇 |
现状与发展 | 16篇 |
预防医学 | 5071篇 |
眼科学 | 1405篇 |
药学 | 19180篇 |
53篇 | |
中国医学 | 5336篇 |
肿瘤学 | 11641篇 |
出版年
2024年 | 456篇 |
2023年 | 2484篇 |
2022年 | 5360篇 |
2021年 | 6143篇 |
2020年 | 5299篇 |
2019年 | 5181篇 |
2018年 | 4973篇 |
2017年 | 4961篇 |
2016年 | 4782篇 |
2015年 | 5292篇 |
2014年 | 7690篇 |
2013年 | 7917篇 |
2012年 | 7093篇 |
2011年 | 8125篇 |
2010年 | 6343篇 |
2009年 | 6322篇 |
2008年 | 6190篇 |
2007年 | 5299篇 |
2006年 | 4465篇 |
2005年 | 4121篇 |
2004年 | 3444篇 |
2003年 | 3066篇 |
2002年 | 2279篇 |
2001年 | 1956篇 |
2000年 | 1605篇 |
1999年 | 1540篇 |
1998年 | 1461篇 |
1997年 | 1418篇 |
1996年 | 1297篇 |
1995年 | 1175篇 |
1994年 | 1089篇 |
1993年 | 1028篇 |
1992年 | 815篇 |
1991年 | 727篇 |
1990年 | 623篇 |
1989年 | 533篇 |
1988年 | 515篇 |
1987年 | 505篇 |
1986年 | 615篇 |
1985年 | 823篇 |
1984年 | 788篇 |
1983年 | 627篇 |
1982年 | 620篇 |
1981年 | 524篇 |
1980年 | 475篇 |
1979年 | 389篇 |
1978年 | 241篇 |
1977年 | 198篇 |
1976年 | 207篇 |
1975年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
Yuan Peng Yuman Li Haiyan Cao Liu Hong Yu Wang Mingxing Xie 《Journal of ultrasound in medicine》2019,38(2):539-544
A pulmonary artery (PA) sling is a very rare congenital cardiovascular anomaly, and only a few studies have reported PA slings in fetuses. The relationship of the PA, aorta, ductus arteriosus, and trachea can be evaluated in the 3‐vessel and 3‐vessel and trachea views during fetal echocardiography. A PA sling can be detected by abnormal positioning of the left PA in relation to the trachea when sweeping from the 3‐vessel view cranially to the 3‐vessel and trachea view. Here we report 3 cases of fetal PA slings and their follow‐ups. Two cases were confirmed by postnatal echocardiography, and the other case was confirmed by a cardiovascular cast after pregnancy termination. We emphasize that the 3‐vessel and 3‐vessel and trachea views are of crucial importance in the prenatal diagnosis of a PA sling. 相似文献
53.
54.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
55.
Zheyuan Wang Zhiheng Shi Lu Zhang Huihan Zhang Yawu Zhang 《Pathology, research and practice》2019,215(3):499-505
Profilin 1 (PFN1) is a critical actin-regulatory protein; however, its functional role in hepatocellular carcinoma (HCC) progression remains to be further elucidated. In the present study, we observed that the expression levels of PFN1 were significantly decreased in HCC tissues and cell lines. Low PFN1 expression was significantly correlated with aggressive clinicopathological characteristics and poor prognosis of HCC patients. Further in vitro experiments demonstrated that overexpression of PFN1 remarkably inhibited the proliferation, migration, invasion and EMT of HCC cells. Moreover, we also found that PFN1 was a direct target gene of miR-19a-3p, and in HCC tissues, and there was a significantly inverse correlation between PFN1 mRNA and miR-19a-3p expression. Collectively, our results showed that PFN1 functions as a tumor suppressor in HCC, and might serve as a diagnostic and therapeutic target for HCC patients. 相似文献
56.
目的:通过3D打印的方法制备的不同重量比例的纳米羟基磷灰石/聚乳酸/聚乙烯醇(n-HA/PLA/PVA)复合膜,并对其相关性能检测。方法:采用3D打印技术制备不同重量比例的n-HA/PLA/PVA复合膜,分别为PLA/PVA复合膜、15%n-HA/PLA/PVA复合膜、50%n-HA/PLA/PVA复合膜、75%n-HA/PLA/PVA复合膜。扫描电镜下观察各组膜形态,对其力学性能、细胞毒性及动物实验相应指标进行检测。结果:扫描电镜下观察,n-HA/PLA/PVA复合膜呈现三维网状结构,各材料间相互结合,孔隙分布不均,大小不一。随着n-HA质量浓度的提高,电镜下见各材料间孔隙逐渐减小,形成结构均匀的复合膜。力学性能及吸水率检测中,随着nHA含量的增加,n-HA/PLA/PVA复合膜的拉伸强度及吸水率呈下降趋势;细胞毒性检测,不同比例复合膜的细胞增殖率无明显差别,无细胞毒性。动物实验测量牙周菌斑指数及龈沟出血指数未发现不同比例n-HA/PLA/PVA复合膜有统计学差异。结论:3D打印不同比例的n-HA/PLA/PVA复合膜具有良好的物理性能和细胞生物相容性,n-HA比例更高的复合膜可能具有更好的物理性能及良好的生物相容性。 相似文献
57.
58.
59.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
60.